Patent SG-11201909728X-A (SG)
Title: Constructs specifically recognizing glypican 3 and uses thereof
Inventor: ZHANG PENGBO
IPC: C07K16/46
Filed: 2018-04-24
Abstract: 35000 - 30000 - „ T 25000 - ‹ 0_ 20000 - LT_ 15000 10000 5000 - 0 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 November 2018 (01.11.2018) WIPO I PCT ill mu °million ono o Immo oimIE (10) International Publication Number WO 2018/200586 Al (51) International Patent Classification: C07K 16/30 (2006.01) GO1N 33/574 (2006.01) CO7K 16/46 (2006.01) A61K 39/395 (2006.01) C07K 19/00 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2018/029221 (22) International Filing Date: 24 April 2018 (24.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/490,586 26 April 2017 (26.04.2017) US (71) Applicant: EUREKA THERAPEUTICS, INC. [US/US]; 5858 Horton Street, Suite 370, Emeryville, California 94608 (US). (72) Inventors: ZHANG, Pengbo; 4659 Rousillon Avenue, Fremont, California 94555 (US). XU, Yiyang; 7652 Chest- nut Way, Pleasanton, California 94588 (US). MORALES, Javier; 1778 Bird Avenue, San Jose, California 95125 (US). NAKANO, Yoko; 10944 San Pablo Avenue, Apt. 723, El Cerrito, California 94530 (US). LIU, Hong; 5573 Wood- view Drive, El Sobrante, California 94803 (US). XIANG, Jingyi; 2170 San Luis Road, Walnut Creek, California 94597 (US). ACKER, Timothy; 1434 Funston Avenue, San Francisco, California 94122 (US). (74) Agent: QI, Yan; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (54) Title: CONSTRUCTS SPECIFICALLY RECOGNIZING GLYPICAN 3 AND USES THEREOF FIG. 6 Competition for Hep2 cell binding with and without soluble GPC3 Without soluble GPC3 MI With soluble GPC3 GPC3A L2K bispecific antibodies (57) : The present application provides constructs comprising an antibody moiety specifically recognizing Glypican 3 (GPC3), C such as a cell surface-bound GPC3. Also provided are methods of making and using these constructs. [Continued on next page] WO 2018/200586 Al MIDEDIMOMMIDIRE101111111111111111111111011111111111111110111111111111 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))